Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “MRSN.”

Based in Cambridge, Massachusetts, Mersana is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADC). Using its Dolaflexin platform, Mersana has generated a pipeline of proprietary ADC product candidates to address cancer patient populations that are not currently amenable to treatment with traditional ADC-based therapies. Its lead product candidate, XMT-1522, is in Phase I clinical trials in primarily breast cancer patients. Mersana has entered into strategic research and development partnerships with Takeda Pharmaceutical Company Limited and Merck KGaA for the development and commercialization of additional ADC product candidates.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Derek Dostal and associates Pedro J. Bermeo, Stephen A. Byeff and Marcus Tan. Partner Rachel D. Kleinberg provided tax advice. Counsel David R. Bauer and associates Bonnie Chen and Arjun Ravi provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices. 

Copy link to share post